ATS (Advanced Tissue Sciences) restructures and creates subsidiary for new challenges
This article was originally published in Clinica
Californian tissue engineering and wound care specialist Advanced Tissue Sciences (ATS) is to realign its existing structure to address new commercial opportunities based around its core technology. The plan is designed to flesh out new strategy aims, which are to move ahead with short and medium-term commercialisation efforts for fibroblast-based products and increase partnership activities with distributors, where necessary. The aim of all this activity is to "bring this company to profitability", says president and CEO Arthur Benvenuto.
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.